Centessa Pharmaceuticals (NASDAQ:CNTA) Now Covered by Analysts at Oppenheimer

Key Points

• Oppenheimer has initiated coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with an "outperform" rating and a price target of $40.00, indicating a potential upside of 141.55% from its current price.
• Despite the positive outlook from Oppenheimer, some analysts have issued mixed ratings, with Chardan Capital setting a target of $30.00 and Wall Street Zen downgrading it to a "sell" rating.
• Centessa Pharmaceuticals has recently reported a loss of $0.38 EPS for the quarter, slightly missing analysts' expectations of a loss of $0.35 EPS while the average target price among analysts stands at $31.50.

Oppenheimer began coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA - Free Report) in a research report report published on Friday. The brokerage issued an outperform rating and a $40.00 target price on the stock.

A number of other research analysts have also issued reports on CNTA. Chardan Capital reaffirmed a "buy" rating and set a $30.00 target price on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Wall Street Zen lowered Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, August 16th. Truist Financial initiated coverage on Centessa Pharmaceuticals in a research report on Monday, July 21st. They issued a "buy" rating and a $30.00 price target for the company. Finally, Needham & Company LLC initiated coverage on Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 price target for the company. Eleven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of "Buy" and an average price target of $31.50.

Centessa Pharmaceuticals Price Performance

NASDAQ:CNTA traded up $0.23 during mid-day trading on Friday, reaching $16.79. 632,847 shares of the stock were exchanged, compared to its average volume of 1,025,817. The business has a fifty day moving average price of $15.70 and a 200 day moving average price of $14.44. Centessa Pharmaceuticals has a 1-year low of $9.60 and a 1-year high of $19.09. The company has a debt-to-equity ratio of 0.32, a current ratio of 10.11 and a quick ratio of 10.12.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.03). As a group, equities analysts expect that Centessa Pharmaceuticals will post -1.6 EPS for the current year.

Insider Activity at Centessa Pharmaceuticals

In related news, insider Mario Alberto Accardi sold 15,000 shares of Centessa Pharmaceuticals stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $14.00, for a total transaction of $210,000.00. Following the completion of the sale, the insider owned 216,485 shares of the company's stock, valued at approximately $3,030,790. This trade represents a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gregory M. Weinhoff sold 10,000 shares of the company's stock in a transaction dated Wednesday, June 25th. The stock was sold at an average price of $13.86, for a total value of $138,600.00. Following the completion of the transaction, the insider directly owned 122,279 shares in the company, valued at approximately $1,694,786.94. The trade was a 7.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 171,322 shares of company stock worth $2,472,814 in the last 90 days. 7.09% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new position in Centessa Pharmaceuticals during the fourth quarter valued at approximately $31,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Centessa Pharmaceuticals by 15,209.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock worth $46,000 after purchasing an additional 3,194 shares during the last quarter. Osterweis Capital Management Inc. bought a new position in shares of Centessa Pharmaceuticals during the 1st quarter valued at $47,000. Barclays PLC raised its holdings in shares of Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after purchasing an additional 4,952 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Centessa Pharmaceuticals in the 1st quarter valued at $147,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.